HIV Evolution, Epidemiology and Prevention

Group Leader

Nuno Taveira

PhD (1996) in Pharmacy (Microbiology), Universidade de Lisboa
Research Associate, IMed.ULisboa, Faculty of Pharmacy of University of Lisbon; Full Professor (Microbiology and Molecular Biology), Instituto Superior de Ciências da Saúde Egas Moniz (ISCSEM), Caparica.

 

The Research

Grupo NTaveiraWe sequence the full-length or partial genomes of HIV-1, HIV-2 and more recently Yellow Fever virus, and use phylogenetic analysis and resistance mutation analysis to characterize the epidemiology, transmission dynamics, diversity and evolution of these viruses in Portugal, Angola, Mozambique and Cape Verde. The epidemiologic data contributes for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), Institute of Health Metrics and Evaluation, Washington, USA. The information on virus diversity is translated into the production/validation of new diagnosis tests, implementation of better treatment regimens, and development of new vaccine candidates. We also perform the pre-clinical evaluation of new vaccine and microbicide candidates and new drugs for the treatment, prevention and cure of HIV infection.

 

 

Ongoing Projects

Source: Fundação Luso-Americana para o Desenvolvimento (Luso-American Collaborative Response Award on HIV/AIDS)
Title: HIV-2 epidemiology, drug resistance and pathogenesis in Cape Verde: the Cape Verde HIV-2 Cohort
PI: Klaus Strebel
Period: Open

Source: NIH, USA (R-00260-15-0)
Title: Reconstructing HIV epidemics from HIV phylogenetics.
PI: Thomas Leitner, Los Alamos National Lab, USA
Period: 2014-2019

Source: Gileads Sciences (GÉNESE Program, 2015)
Title: Induction of neutralizing antibodies in rabbits with a new type of HIV-1 vaccine.
PI: Nuno Taveira, Egas Moniz, CRL
Period: 2016-2018

Source: Bristol Meyers Squibb (BMS Partnering for cure Program)
Title: Gene therapies for HIV cure using RNA replicons targeting HIV entry and latency.
PI: Pedro Borrego, iMEd.ULisboa
Period: 2015-2017

Source: Gilead Sciences (GÉNESE Program, 2014)
Title: COMBI-VIH: nanoplatform for the modulation of immune cells for the control of HIV infection
PI: Helena Florindo, iMed.ULisboa
Period: 2015-2017

Recent Most Relevant Publications

 

GBD 2015 Healthcare Access and Quality Collaborators. 2017. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. May 18. pii: S0140-6736(17)30818-8. [Epub ahead of print]

Borrego P., Gonçalves M.F., Gomes P., Araújo L., Moranguinho I., Figueiredo I.B., Barahona I., Rocha J., Mendonça C., Cruz M.C., Barreto J., Taveira N. 2017. Assessment of the Cavidi ExaVir™ Load assay for monitoring plasma viral load in HIV-2 infected patients J Clin Microbiol. 2017 May 17. pii: JCM.00235-17. [Epub ahead of print].

Kraemer M.U.G., Faria N.R., Reiner Jr. R.C., Golding N., Nikolay B., Johansson M.A., Salje H.0., Faye O., Wint G.R.W., Niedrig M., Shearer F.M., Hill S.C., Thompson R.N., Bisanzio D., Taveira N., Nax H.H., Pradelski B.S.R., Murphy N.R., Bogoch I.I., Khan K., Brownstein J.S., Tatem A.J., de Oliveira T. Smith D.L., Sall A., Pybus O.G., Hay S.I., Cauchemez S. 2016. Spread of Yellow Fever Virus outbreak in Angola and the Democratic Republic Congo 2015-2016: a modelling study. Lancet Infect Dis. 2017. 17: 330-338.

Xiong S., Borrego P., Ding X., Zhu Y., Martins A., Chong H., Taveira N., He Y. 2016. A Helical Short-Peptide Fusion Inhibitor with highly potent activities against HIV-1, HIV-2 and Simian Immunodeficiency Virus. J. Virol. 2016 91(1). pii: e01839-16.

Chen C-Y, Shingai M., Martin M.A., Borrego P., Taveira N., Klaus Strebel K. 2016. Antagonism of BST-2/tetherin is a conserved function of the Env glycoprotein of primary HIV-2 isolates. J. Virol. 2016 90:11062-11074.

Group Members

Master Students

  • Ifeanyi Jude Ezeonwumelu
  • Susana Tracana